Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 5/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | BLVRB | P30043 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725525 | 0.87 | KDM4E (0.46) | MGAMNPC1RAB9AACMSDKDM4E | |
| SCHEMBL319073 | 0.82 | KDM4E (0.52) | MGAMNPC1RAB9AACMSDKDM4E | |
| SCHEMBL1711474 | 0.81 | KMO (0.44) | ACMSDKDM4EALOX15TSHRTDP1 | |
| SCHEMBL29533318 | 0.81 | KDM4E (0.50) | MGAMACMSDKDM4EALOX15TSHR | |
| SCHEMBL318608 | 0.81 | KDM4E (0.50) | MGAMACMSDKDM4EALOX15TSHR | |
| SCHEMBL1711387 | 0.80 | KMO (0.54) | ACMSDKDM4ECTSAADORA2ALDHA | |
| SCHEMBL117174 | 0.78 | ADORA2A (0.48) | KDM4ETSHRADORA2ACSNK2A2CSNK2B | |
| SCHEMBL1910539 | 0.78 | HSD17B14 (0.40) | ACMSDKDM4EALOX15TSHRTDP1 | |
| SCHEMBL319710 | 0.76 | CTSA (0.56) | ACMSDKDM4EALOX15TSHRTDP1 | |
| SCHEMBL1712177 | 0.76 | PIM1 (0.44) | MGAMACMSDKDM4EALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| EP-2344474-B1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20140079693-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-03-20 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| CN-102203079-A | Pyridine carboxamide derivatives as kinase inhibitors | NOVARTIS AG | 2011-09-28 | — | — | CN | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079693-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MGAM 1753/4885NPC1 4503/4885RAB9A 2986/4885 |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MGAM 1753/4885NPC1 4503/4885RAB9A 2986/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | MGAM 1753/4885NPC1 4503/4885RAB9A 2986/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MGAM 1831/4885NPC1 4325/4885RAB9A 4183/4885 |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MGAM 1753/4885NPC1 4503/4885RAB9A 2986/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MGAM 1831/4885NPC1 4325/4885RAB9A 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.